ACHIEVE‑4: oral GLP‑1 orforglipron matched insulin glargine for glycemic control

Diabetes drugs are in the middle of a format fight — pills versus injections — but the real question is whether the pill can hold up on hard outcomes, not just convenience. That is what ACHIEVE-4 was built to test. On April 16, Eli Lilly said its once-daily oral GLP-1 orforglipron, sold as Foundayo, matched insulin glargine on the trial’s cardiovascular safety target and also beat it on glucose, weight, and several cardiometabolic measures. (investor.lilly.com) ### What is orforglipron, exactly? Orforglipron is a small-molecule GLP-1 receptor agonist taken as a pill once a day. That matters because most powerful GLP-1 drugs have been injections, and oral semaglutide still comes with strict fasting and timing rules. Lilly has been pushing orforglipron as a simpler oral option that does not need those food and water restrictions. (investor.lilly.com) ### What was ACHIEVE-4 testing? This was a Phase 3 head-to-head study against insulin glargine in adults with type 2 diabetes plus obesity or overweight who also had increased cardiovascular risk. More than 2,700 participants across 15 countries were randomized to dose-escalated oral orforglipron or treat-to-(investor.lilly.com)ual heart attack, stroke, or cardiovascular death composite. (investor.lilly.com) ### So what changed? The big news is that the cardiovascular safety box got checked. ACHIEVE-4 met its prespecified noninferiority goal for major adverse cardiovascular events versus insulin glargine, with a hazard ratio of 0.84 and a 95% confidence interval of 0.59 to 1.20. In plain English, the pill did not show excess cardiovascular risk against a standard basal insulin in a higher-risk population. (investor.lilly.com) ### Did it also help blood sugar? Yes — and that is why the result is more interesting than a narrow safety win. Lilly said orforglipron delivered greater A1C reductions than insulin glargine at week 52 and kept that advantage through week 104, while more patients reached A1C below 7%. The company also said p(investor.lilly.com)mparison. (investor.lilly.com) ### What about the mortality result? This is the eye-catching part, but also the part to treat carefully. ACHIEVE-4 showed lower all-cause mortality with orforglipron — hazard ratio 0.43, or roughly a 57% relative reduction. But this was a topline release, not a full peer-reviewed paper, and nominally significant findings outside the main hierarchy can fade once the full dataset is adjudicated and picked apart. (hcplive.com) ### Why compare against insulin glargine? Because glargine is a real-world workhorse. It is what many patients move to when oral drugs are no longer enough, especially when clinicians want strong glucose lowering without waiting for newer agents to prove themselves in tougher populations. If a pill can stand next to basal insulin on safety and still win on A1C and weight, that changes the treatment conversation. (clinicaltrials.gov) ### Where does this fit in Lilly’s bigger plan? ACHIEVE-4 is part of a broader Phase 3 program that has already produced positive diabetes readouts for orforglipron. Lilly said these results support a diabetes filing to the FDA by the end of Q2 2026. So this is not just one nice trial result — it is part of the package meant to turn orforglipron into a major commercial and clinical rival in the oral incretin market. (investor.lilly.com) ### Bottom line ACHIEVE-4 says the pill version is getting real. Orforglipron was not just convenient — it looked cardiovascularly safe against insulin glargine and stronger on the outcomes patients feel day to day, especially A1C and weight. The catch is that the most dramatic signal — lower mortality — still needs the full data reveal. (investor.lilly.com)